242
Views
17
CrossRef citations to date
0
Altmetric
Rapid Communication

Interferon-γ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital

, , , , , , & show all
Pages 943-945 | Received 04 Jun 2010, Accepted 30 Aug 2010, Published online: 11 Oct 2010
 

Abstract

The aim of this study was to evaluate the annual incidence of tuberculosis infection among newly employed doctors and nurses in Korea. The annual incidence of tuberculosis infection ranged from 3.3% to 5.7%, based on the definition of conversion of an interferon-γ release assay, which suggests that stricter preventive strategies against nosocomial TB infection should be employed. Follow-up interferon-γ levels measured after 3 months of isoniazid and rifampicin treatment showed considerable variation. Therefore, serial testing with interferon-γ release assays after treatment of latent TB infection may be insufficient for evaluating the effects of treatment due to the variable responses.

Acknowledgements

This study was supported by the Samsung Medical Center Clinical Research Development Program grant (CRS-108-01-1). We thank Ms Sook Young Woo (Biostatistics Team, Samsung Biomedical Research Institute, Samsung Medical Center) for statistical analysis.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.